Navigation Links
Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting

gnificant, in favor of the satraplatin arm.

PFS data as observed by the clinical site investigators were also presented today. Compared to the PFS data previously reported, these progression events were not adjudicated by the blinded independent review committee. The hazard ratio for PFS for the intent-to-treat population per investigator observation was 0.58 (95% CI: 0.50-0.67, p = 0.000000000002). Median time to progression was 16.0 weeks for the satraplatin arm versus 6.0 weeks for control. The hazard ratio for PFS for the intent-to-treat population treated with prior Taxotere(R) (docetaxel) per investigator observation was 0.52 (95% CI: 0.42-0.65, p=0.000000002), with a median time to progression of 15.3 weeks for the satraplatin arm compared to 5.6 weeks for control. These data are consistent with the PFS outcomes as adjudicated by the blinded independent review committee.

Safety findings in the SPARC trial were consistent with previous clinical studies involving satraplatin. Myelosuppression (decrease in the production of blood cells by the bone marrow) was the most common adverse reaction associated with satraplatin therapy. Twenty-one percent of patients in the satraplatin arm experienced grade 3 or 4 thrombocytopenia; 14% had grade 3 or 4 leucopenia and 21% had grade 3 or 4 neutropenia. Gastrointestinal disorders were the most frequent non-hematological adverse events (occurring in 57.9% of the patients receiving satraplatin). Eight percent of patients in the satraplatin arm experienced grade 3 or 4 gastrointestinal toxicities, including nausea (1.3%), vomiting (1.6%), diarrhea (2.1%) and constipation (2.1%). Additionally, 5% or less of patients in the satraplatin arm experienced grade 3 or 4 fatigue (1.7%), grade 3 or 4 infections (4.0%) and pulmonary/respiratory grade 3 or 4 toxicities (3.0%).

Preliminary data from Phase 2 trial evaluating satraplatin plus Taxol in non-small cell lung cancer also published in ASCO educational book


'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:10/30/2014)... 30, 2014 China Biologic Products, Inc. (NASDAQ: ... integrated plasma-based biopharmaceutical company in China ... third quarter 2014 financial results on Wednesday, November 5, ... Company,s management will hold a conference call at 7:30 ... is 8:30 p.m., Beijing Time on November 6, 2014, ...
(Date:10/30/2014)... 30, 2014 Extensiv ... Aufbau von Kuhmilchverträglichkeit     Kuhmilchproteinallergie (KMPA) ... Säuglingen und Kleinkindern. Der bisher übliche Umgang ... der Babys bzw. deren stillenden Mütter Milchproteine ... sich bei einer beträchtlichen Anzahl von Kindern ...
(Date:10/30/2014)... 2014  TWi Pharmaceuticals, Inc. today announced that it ... and Drug Administration (FDA) on its Abbreviated New Drug ... the generic equivalent to Eisai Inc.,s Aricept® 23mg.  Aricept® ... TWi Pharmaceuticals is preparing to launch the product ... Pharmaceuticals USA , at the earliest ...
Breaking Medicine Technology:China Biologic to Report Third Quarter 2014 Financial Results 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3
... CITY, Md., Oct. 11, 2011 Christine K. Pierre, ... a "Professional Woman of the Year" by the National ... recognizes Pierre,s "outstanding leadership and commitment" within her profession, ... women. Pierre founded RxTrials, Inc., in 1994, ...
... Johnson (NYSE: JNJ ) will host a conference ... Tuesday, October 18, 2011, to review third-quarter results.  Dominic Caruso, ... Vice President, Investor Relations, will host the call. ... visiting the Company,s website at www.investor.jnj.com . ...
Cached Medicine Technology:Christine Pierre Selected as "Professional Woman of the Year" 2
(Date:10/30/2014)... 30, 2014 Victory Healthcare, a ... 2014 third quarter infection rates and patient satisfaction ... rates of only two percent or less, and ... exceeding 98 percent. , “We are delighted with ... rising satisfaction scores,” said Robert Helms, chairman and ...
(Date:10/30/2014)... Oct. 29, 2014 (HealthDay News) -- Scientists who used ... laboratory say their breakthrough could provide a new way ... stomach diseases. The team used human pluripotent stem ... in the body -- to grow the functional miniature ... bacteria, a major cause of ulcers and stomach cancer. ...
(Date:10/30/2014)... Many U.S. colleges have indoor tanning salons on ... risk for skin cancer, researchers report. Tanning ... so colleges should adopt tanning-free policies, to help ... health efforts are needed to raise university administration ... indoor tanning poses to young adults in order ...
(Date:10/30/2014)... (HealthDay News) -- A new vaccine that could help ... approved by the U.S. Food and Drug Administration on ... the ages of 10 and 25 from invasive meningococcal ... bacteria. The bacteria can infect the bloodstream (sepsis) ... brain. It is a leading cause of bacterial meningitis, ...
(Date:10/29/2014)... The development of minimally and even non-invasive technologies is ... for instance, to carry out a range of operative ... scalpel, leaving only tiny scars as a result. Similar ... active agents to patients – instead of using injections ... be possible to supply them via a plaster which ...
Breaking Medicine News(10 mins):Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2Health News:FDA Approves New Vaccine to Protect Against Meningitis 2Health News:Gentle caffeine boost for premature babies 2
... during and after treatment resulted in less fatigue, greater ... - Exercise during and after treatment improves quality of ... or prostate cancer, a new study finds. , "Using ... potential to benefit patients both physically and psychologically, as ...
... ... 7,000 stores in under five months of operation. The site offers 30,000 coupons from 7,000 ... 500 votes per day, making it one of the fastest growing coupons/deals sites ever. ... (PRWEB) May 27, 2010 ...
... , THURSDAY, May 27 (HealthDay News) -- A new ... that many people don,t know enough about sun damage ... survey showed that despite our repeated warnings about the ... sun protection, many people could not correctly answer true/false ...
... ... and published by Random House Mondadori this ,practical guide teaches Latina women how to ... ... Guía Para Vestir Mejor (Discover Your Style: Your Guide to Dressing Better) written ...
... "color-coded" laboratory mice are providing researchers with a novel ... monitor the cellular immune responses of transplanted tissue in ... the June issue of Nature Medicine , which ... a key consideration in developing strategies to improve transplant ...
... at the UCLA Medical Center found that antiviral therapy ... is the most cost-effective approach to treating patients with ... Full details appear in the June issue of ... behalf of the American Association for the Study of ...
Cached Medicine News:Health News:Exercise Boosts Health of Cancer Patients 2Health News:Coupon Site TrimBack.com Adds 7000th Online Store 2Health News:Many People Still Don't Know How to Protect Against Skin Cancer 2Health News:"Descubre Tu Estilo: Tu Gua Para Vestir Mejor" Wins Triple Crown Award and Honors at the 12th International Latino Book Awards 2Health News:"Descubre Tu Estilo: Tu Gua Para Vestir Mejor" Wins Triple Crown Award and Honors at the 12th International Latino Book Awards 3Health News:Color-coded tracking method helps scientists analyze outcomes of newly transplanted tissue 2Health News:Color-coded tracking method helps scientists analyze outcomes of newly transplanted tissue 3Health News:Antiviral therapy during compensated cirrhosis most cost-effective approach 2
... 1-step, hand-held, point-of-care device for the qualitative detection ... The TOX/See device can detect up to ... 3 to 8 minutes and requires only a ... individually packaged to maximize convenience and ease of ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
Medicine Products: